Entera Bio(ENTX) - 2025 Q1 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to WASHINGTON, D.C. 20549 Commission file number: 001-38556 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ENTERA BIO LTD. (Exact name of Registrant as specified in its charter) For the quarterly period ended March 31, 2025 OR Indicate by check mark whether the registrant is a shell comp ...